focus -WSS

focus

author：knowledge 2025-09-29 21:25:30 - browse：3

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Readout Newsletter: Biotech news, including Moderna's Covid vaccine

entertainment

WSS

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

The future of health care in the House

Why age limits for politicians are a terrible idea

My yearlong odyssey to get my son’s ADHD medication covered

Parkinson’s finding may lead to tests and, someday, treatments

Francis Collins on trust in science and how Covid communications failed

hotspot

focus

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The future of health care in the House

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Humana cuts profit projections as Medicare Advantage costs soar

State Dept. review finds Biden bears some blame for Afghanistan failures

Research misconduct: Proposed new rules face resistance

Novavax promises a turnaround & Lilly roils the obesity market

Why Charlie Gard's case is so disturbing to Americans

The high cost of giving birth even with insurance

Chan Zuckerberg Biohub Chicago to focus on inflammation

hotspot

Think you might have Covid

How digital therapeutics firms are pivoting after Pear's bankruptcy

What to expect at HLTH 2023, the health care industry conference

Chemotherapy drug shortage eases slightly but still widespread

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

VC firm General Catalyst wants to buy a health system

knowledge

explore

entertainment

leisure time